Choose a language and wait for the translated text.
The court said that the rival products under the two marks are identical with the same API (active pharmaceutical ingredient) and are used for treating Type-2 diabetes Mellitus.
HC Rules in Favour of DRL in Trademark Row with Razenta | PharmaVoice
